Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial

Table 2 Univariable analysis for the risk factors of EBV and CMV infections post-transplantation

Parameters	EBV-DNAemia	EBV-associated disease	CMV-DNAemia	CMV-associated disease
Gender	P=0.679	P=0.125	P=0.385	P=0.844
Female vs male	P=0.679	P=0.125	P=0.385	P=0.844
Patient age	P=0.687	P=0.881	P=0.137	P=0.694
< 35 vs ≥ 35 years	P=0.687	P=0.881	P=0.137	P=0.694
EBV serostatus	P=0.067	P=0.502	--	--
D−/R+ vs other	P=0.067	P=0.502	--	--
CMV serostatus	--	--	P=0.573	P=0.797
D−/R+ vs other	--	--	P=0.573	P=0.797
CR status at transplant	P=0.163	P=1.000	*P=0.025	P=0.455
≥ CR2 vs CR1	P=0.163	P=1.000	*P=0.025	P=0.455
ATG use in the conditioning^#	*P<0.001	*P=0.036	*P<0.001	P=0.985
ATG vs no ATG	*P<0.001	*P=0.036	*P<0.001	P=0.985
Sorafenib pre-transplant	P=0.349	P=0.727	P=0.085	P=0.296
Use vs no use	P=0.349	P=0.727	P=0.085	P=0.296
Sorafenib post-transplant	P=0.853	P=0.628	P=0.892	P=0.702
Sorafenib vs control	P=0.853	P=0.628	P=0.892	P=0.702
aGVHD^&	P=0.417	P=0.196	*P=0.004	*P=0.023
cGVHD^&	P=0.891	P=0.190	P=0.248	P=0.120

Abbreviations: EBV Epstein-Barr virus, D donor, R recipient, CMV cytomegalovirus, CR complete remission, CR2 second CR, CR1 first CR, ATG antithymocyte immunoglobulin; aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD. *P<0.05. ^#All patients undergoing haploidentical donor (HID)/HLA-matched unrelated donor (MUD) transplants received ATG as GVHD prophylaxis, and none of those undergoing HLA-matched sibling donor (MSD) transplants received ATG as GVHD prophylaxis. Considering there was collinearity between transplant modality (HID/MUD vs MSD) and ATG use in the conditioning (ATG vs no ATG), we only included ATG use in the conditioning in the analysis of risk factors for EBV/CMV infections. ^&Time-dependent covariate

ISSN: 1741-7015